# Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer

> **NCT02963090** · PHASE2 · TERMINATED · sponsor: **Alliance Foundation Trials, LLC.** · enrollment: 9 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Topotecan
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02963090
- **Lead sponsor:** Alliance Foundation Trials, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-20
- **Primary completion:** 2019-06-20
- **Final completion:** 2019-08-20
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Lack of enrollment
- **Last updated:** 2023-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02963090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02963090, "Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02963090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*